Patient-centric dose equivalency pilot study of incobotulinumtoxin a(xeomin)vs.abobotulinumtoxin a(dysport)in the treatment of glabellar frown lines  

作　　者：Jonathan Bank Nicole A.Phillips Laurie A.Casas 

机构地区：[1]Department of Surgery,Section of Plastic and Reconstructive Surgery,University of Chicago Medical Center,Chicago,IL 60026,USA [2]Department of Surgery,Division of Plastic Surgery,Brigham and Women’s Hospital,Boston,MA 02115,USA

出　　处：《Plastic and Aesthetic Research》2015年第1期12-16,共5页整形与美容研究（英文版）

摘　　要：Aim:Incobotulinumtoxin A(xeomin)has been proposed as an alternative to abobotulinumtoxin A(dysport)and onabotulinumtoxin A(Botox)in the treatment of glabellar frown lines.A recent study is comparing abobotulinumtoxin A and onabotulinumtoxin A revealed equivalent efficacy with a dose conversion ratio of 2.5:1.We sought to establish effectiveness and dosing equivalency of incobotulinumtoxin A vs.abobotulinumtoxin A.Methods:Inclusion criteria for this pilot study included patients of a single surgeon(LAC)who had previously received a constant dose of abobotulinumtoxin A over at least four consecutive treatment sessions for the previous 12 months to achieve an 85-90%elimination of dynamic glabellar frown lines.The primary outcome sought dose comparison between established maintenance abobotulinumtoxin A dosing and incobotulinumtoxin A first-time dosing.A 2:1 conversion(abobotulinumtoxin A:incobotulinumtoxin A)was chosen in most patients.Secondary outcomes were patient-reported onset of effect,physician-assessed effect at 10-12 weeks,pain associated with administration,and patient perceived need for re-treatment at 2 weeks.Results:A total of 32 subjects were included.The mean dose of incobotulinumtoxin A was 17.1 units(±6.1,the median dose 20 units).The mean dose of abobotulinumtoxin A was 27.6(±11.7,the median dose 27.5 units).The mean difference in treatment units was 10.5(95%confidence interval,P<0.001).Among 30 patients who reported effect onset,the median was 8.5 days,with a range of 1-14.At 10-12 weeks,muscle paralysis was assessed to be 69.2%(±27.3),vs.90.3%(±1.8)with abobotulinumtoxin A(P<0.001).The majority of patients rated pain of administration as equal or greater to that of abobotulinumtoxin A(63%and 22%,respectively).Three patients(9%)required re-treatment at 2 weeks with abobotulinumtoxin A due to lack of effective treatment with incobotulinumtoxin A.Abobotulinumtoxin A re-treatment was chosen by the patient.Conclusion:We found incobotulinumtoxin A at 17.1(±6.1)units to be less effective than abobo

关 键 词：Abobotulinumtoxin A glabellar frown lines incobotulinumtoxin A rhytids 

分 类 号：G63[文化科学—教育学]